1 ay smooth muscles in the lung and acts as an antiasthmatic.

2 ihyperlipidemics (34%), antiulcerants (33%), antiasthmatics (32%), antihypertensives (26%), antidepre

3 ents EIB in a dose-dependent manner; and its antiasthmatic activity is independent of its effect on p

4 such as montelukast or zafirlukast show good antiasthmatic activity over a wide spectrum of asthma se

5  has on the airway and whether its potential antiasthmatic activity would be similar to other PGEs.

6 ch antagonists have therapeutic potential as antiasthmatic agents.

7                            Because PGE(2) is antiasthmatic and PGD(2) is proasthmatic, we speculate t

8 sought for their potential antiinflammatory, antiasthmatic, and antiischemic properties.

9         Other medications--antihypertensive, antiasthmatic, antidepressant, antihyperlipidemic, antiu

10 nd IL-13 and may be an attractive target for antiasthmatic drugs.

11 nosine receptor, which have the potential as antiasthmatic or antidiabetic drugs, we have synthesized

12 ght serve as a target for novel antiallergic/antiasthmatic therapies.

13  blocked by enprofylline (Ki = 7 microM), an antiasthmatic xanthine with low affinity (Ki > 100 micro

14                      The K(I) values for the antiasthmatic xanthines, theophylline (7.8 microM) and e